
News|Articles|May 1, 2002
No advantage to omapatrilat over enalapril in heart failure . . .
The investigational vasopeptidase inhibitor omapatrilat is as effective as enalapril in preventing major adverse cardiac outcomes in patients with moderate to severe heart failure, but failed to show superiority, said Milton Packer, MD.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
2
A conversation with Dolores Malaspina, M.D., about the generational impact of Holocaust trauma on schizophrenia risk
3
Intervention boosts connected insulin pen adoption among minorities with Type 1 diabetes
4
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
5


























